Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cinclus Pharma Holding AB ( (SE:CINPHA) ) just unveiled an announcement.
Cinclus Pharma Holding AB announced the upcoming release of its second-quarter report for 2025, scheduled for August 20, accompanied by a live presentation from the CEO and CFO. This event will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a late-stage clinical pharmaceutical company focused on developing drugs for acid-related diseases and disorders of the upper gastrointestinal tract. Their leading drug candidate, linaprazan glurate, aims to treat gastroesophageal reflux disease (GERD) more effectively than existing treatments. The company is preparing for phase III studies of this drug, targeting a significant market need in the US and EU.
Average Trading Volume: 133,917
Technical Sentiment Signal: Buy
For an in-depth examination of CINPHA stock, go to TipRanks’ Overview page.